HOME >> MEDICINE >> NEWS
American Heart Association Comment On New England Journal Of Medicine Report OnCalcium Antagonist Nisoldipine (March 5 issue)

revention and progression of diabetes in equal number of individuals. A secondary goal of the study was to determine if the drugs could prevent cardiovascular disease, a leading cause of death among individuals with diabetes.

The study found that nisoldipine (Sular) was linked with a higher rate of fatal and non-fatal heart attacks -- a total of 25 compared to five for enalapril in this particular group. Despite these striking differences, the authors of the study stress that "it is plausible that the findings resulted from a protective effect of enalapril and not a deleterious effect of nisoldipine."

Other calcium antagonists include: nimodipine (Nimotop); verapamil (Calen, Isoptin, Verelan); nicardipine (Cardene); diltiazem (Cardizem, Dilacor); isradipine (DynaCirc); amlodipine (Norvasc); felodipine (Plendil); nifedipine (Procardia); and bepridil (Vascor).


'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-705-1279
American Heart Association
3-Mar-1998


Page: 1 2

Related medicine news :

1. Consumers with disabilities empowered by American Disabilities Act
2. Definition of persistent vegetative state available from American Academy of Neurology
3. African-American women with endometrial cancer have more aggressive cancer than Caucasian women
4. New colorectal cancer screening recommendations for African Americans
5. American Thoracic Society Journal news tips for March 2005 (second issue)
6. Community care tops medical care at preventing heart disease in black Americans
7. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
8. Obesity among African-American stroke survivors increases risk factors for recurrent stroke
9. Awards & fellowships at the International & American Association for Dental Research General Session
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology

Post Your Comments:
(Date:5/24/2015)... (PRWEB) May 24, 2015 For people ... and Chinese Enterokinase Industry, 2009-2019 Market Research Report would ... is an exhaustive study on the present market scenario ... insight into the growing Chinese market of this industry. ... the overall status of the manufacturers in this industry. ...
(Date:5/24/2015)... EnviroLeather™ by LDI, a leader ... a classic, rugged leather grain with enhanced stain ... including ink, to be easily removed. The collection ... corporate, healthcare, hospitality and education environments. , InkGard ... of developing products that are more sustainable, less ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/24/2015)... 2015 A report out just ... single best option for avoiding cardiovascular disease is exercise ... was the single most powerful predictor of death and ... diabetes and family history of premature death -- a ... and lung fitness. , The Importance of Cardiovascular Screening ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2
(Date:5/22/2015)... 2015  The U.S. Food and Drug Administration,s ... first biosimilar product approved in the ... in the contract manufacturing organization (CMO) industry, according ... geared to the production of small-molecular drugs and ... The healthcare market research publisher,s report, Biopharmaceutical ...
(Date:5/22/2015)... 22, 2015 According to a ... Product (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, ... Cytometry), by End Users - Global Forecast to 2020", ... expected to reach $736.85 Million by 2020 from $452.36 ... Browse 71 market data Tables and ...
(Date:5/22/2015)... 22, 2015 Today, Rhodes Pharmaceuticals L.P. announced ... stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder ... 2015. The announcement comes just ... the U.S. Food and Drug Administration (FDA). ... of methylphenidate capsule with an onset of effect ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
Cached News: